Clinical Study
The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
Table 2
Change of parameters after administration of liraglutide.
| | Liraglutide group (N = 26) | | | Variables (N) | Before administration | After administration | Paired t-test | | P value |
| | Body weight* (kg) | 81.8 (74.4–92.3) | 78.0 (72.1–88.5) | <0.01 | | BMI* (kg/m2) | 30.1 (26.8–32.1) | 28.6 (25.5–31.6) | <0.01 | | AST* (IU/mL) | 50 (32–59) | 35 (29–39) | <0.01 | | ALT* (IU/mL) | 65 (52–74) | 48 (34–61) | <0.01 | | -GTP* (IU/mL) | 98 (55–127) | 90 (48–130) | 0.44 | | Fast blood glucose* (mg/dL) | 207 (151–256) | 168 (116–199) | 0.02 | | HbA1c (%) | 8.4 (7.4–9.4) | 7.6 (6.9–8.4) | 0.01 | | LDL-cholesterol* (mg/dL) | 103 (78–116) | 99 (78–115) | 0.51 | | Triglyceride* (mg/dL) | 199 (125–283) | 175 (114–231) | 0.19 | | Platelet count* (/L) | 204 (183–230) | 207 (173–224) | 0.67 | | APRI index* | 0.73 (0.37–0.91) | 0.49 (0.34–0.56) | <0.01 |
|
|
BMI: body mass index; AST: aspartate aminotransferase; ALT: alanine aminotransferase; -GTP: -glutamyl transpeptidase; HbA1c: hemoglobin A1c; APRI: AST-to-platelet counts ratio index.
|
